基于动态对比增强MRI的影像组学能否有效预测乳腺癌新辅助化疗反应:一项Meta分析
该Meta分析纳入7项研究共1272例患者,评估基于动态对比增强MRI的影像组学预测乳腺癌新辅助化疗后病理完全缓解的诊断准确性。汇总敏感度为81%(95%CI 73-87%),特异度为74%(95%CI 54-88%),AUC为0.83(95%CI 0.80-0.86)。作者认为该工具具有较好的预测效能,提倡将其作为补充资源用于辅助临床决策。
要点
- 基于DCE-MRI的影像组学预测乳腺癌新辅助化疗后pCR的汇总AUC为0.83(95%CI 0.80-0.86)。
- 汇总敏感度81%(95%CI 73-87%),特异度74%(95%CI 54-88%)。
- 3.0 T研究较1.5 T/3.0 T研究敏感度略低但特异度明显更高,PLR和DOR在3.0 T更高。
核心结论
- 基于DCE-MRI的影像组学分析对乳腺癌新辅助化疗后达到病理完全缓解显示出较好的预测效能,作者提倡将该工具作为补充资源整合到临床决策过程中。
研究设计与样本
- Meta分析,纳入7项研究共1272例病例,检索PubMed、Web of Science和Cochrane Library数据库截至2023年9月发表的相关研究,按纳入标准筛选。
诊断标准与关键数值
- 汇总诊断效能:敏感度81%(95%CI 73-87%),特异度74%(95%CI 54-88%),阳性似然比3.1(95%CI 1.6-6.1),阴性似然比0.26(95%CI 0.17-0.39),诊断比值比12(95%CI 5-31),AUC 0.83(95%CI 0.80-0.86)。按MRI场强分层:3.0 T研究较1.5 T/3.0 T研究敏感度略低但特异度明显更高,PLR和DOR在3.0 T更高。按图像采集时间分层:新辅助化疗前联合其他时间点较仅用新辅助化疗前显示更好的DOR和PLR表现。
临床应用与阅片要点
- 作者提倡将基于DCE-MRI的影像组学作为补充资源整合到临床决策过程中,以辅助和增强临床决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aimed to evaluate the diagnostic accuracy of radiomics based on dynamic contrast-enhanced MRI (DCE-MRI) in predicting pathological complete response (pCR) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC).
MATERIALS AND METHODS: Relevant studies published up until September 2023, were searched in the PubMed, Web of Science, and The Cochrane Library databases, and screened based on inclusion criteria. The diagnostic performance of radiomics was evaluated using pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR).
RESULTS: The analysis included 7 studies with a total of 1272 cases. Pooled estimates suggested overall diagnostic accuracy of radiomics in detecting pCR were determined: sensitivity, 81% (95% CI, 73-87%); specificity, 74% (95% CI, 54-88%); PLR, 3.1 (95% CI, 1.6-6.1); NLR, 0.26 (95% CI, 0.17-0.39); DOR, 12 (95% CI, 5-31); and AUC, 0.83 (95% CI, 0.80-0.86). By MRI field, studies using 3.0 T showed slightly lower sensitivity compared to those using 1.5 T/3.0 T, but notably higher specificity in comparison, and PLR and DOR were higher when using 3.0 T than when using 1.5 T/3.0 T. By image acquisition time, combining pre-NAC with other time points showed better DOR and PLR performance than using pre-NAC alone.
CONCLUSIONS: The radiomics analysis based on Dynamic Contrast-Enhanced MRI (DCE-MRI) demonstrated substantial predictive efficacy for achieving pathological complete response (pCR) following neoadjuvant chemotherapy in breast cancer. Consequently, we advocate for the integration of this tool as a supplementary resource to inform and enhance clinical decision-making processes.
引用
- Ye T, Jin S, Xu H, et al. Can radiomics from dynamic contrast-enhanced MRI effectively predict response to neoadjuvant chemotherapy in breast cancer?: A meta-analysis. Clin Radiol. 2025. PMID: 41240819. doi:10.1016/j.crad.2025.107085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。